Week of June 1st, 2021 | Vol. 10, Issue 22
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory
INDUSTRY M&A SNAPSHOT

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.

For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
MARKET REPORTS
Recent Materials Providing Insight Into Healthcare Related Industries
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America

Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics

Project Aspen
Sell-side | CDMO | Multinational CDMO headquartered in US

Project Athena
Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse
Prestige Consumer Healthcare has agreed to acquire specialty pharmaceuticals provider Akorn Operating Company’s Consumer Health business for approximately $230m.

Prestige Consumer Healthcare has agreed to acquire specialty pharmaceuticals provider Akorn Operating Company’s Consumer Health business for approximately $230m.

Under the terms of a definitive agreement signed by the companies, Prestige will buy Akorn’s over-the-counter brands TheraTears, Diabetic Tussin, MagOx, Multi-betic and Zostrix.

RECENT INDUSTRY TRANSACTIONS
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
15 transactions totaling $2,268 million
Supplies, Equipment & Services
30 transactions totaling $965 million
Healthcare IT & Managed Care
8 transactions totaling $17 million
Healthcare Facilities & Distributors
16 transactions totaling $3,033 million
Pharma & Biotech
28 transactions totaling $871 million
Supplies, Equipment & Services
33 transactions totaling $1,186 million
Healthcare IT & Managed Care
14 transactions totaling $408 million
Healthcare Facilities & Distributors
6 transactions totaling $529 million
Pharma & Biotech
27 transactions totaling $2,234 million
Supplies, Equipment & Services
4 transactions totaling $493 million
Healthcare IT & Managed Care
2 transactions totaling $144 million
Healthcare Facilities & Distributors
0 transactions
INDUSTRY TRADING COMPS
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
RECENT INDUSTRY TRANSACTIONS
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
June 1, 2021 - Fierce Biotech
Novartis has signed up to a collab pact and possible buyout deal, should all go to plan, for quiet, little-known Swiss biotech Cellerys. The Zurich-based company is working on new multiple sclerosis drug, CLS12311, which is currently in phase 2. Novartis is pairing up with the biotech on the asset but nabs “the option to acquire Cellerys upon completion of a phase 2 trial in the coming years.”

May 28, 2021 - Fierce Pharma
Moderna partnered with Samsung Biologics to help it with fill-finish work of its mRNA COVID-19 vaccine for supply to locations outside the U.S. Astellas dialed up peak sales estimates for cancer drugs Xtandi and Padcev in a new five-year plan. Novo Holdings co-led a $200 million investment round in Singapore-based Esco Lifesciences, which plans to build a cell and gene therapy tech hub in Boston.

May 27, 2021 - Contract Pharma
August Bioservices, LLC, a CDMO providing drug discovery, development, and pharmaceutical manufacturing services, closed a $23.6 million Series A extension, led by Polaris Partners. The proceeds will go toward expanding August’s manufacturing capacity and capabilities to advance the technology platforms needed to support production of sterile injectable medications.

May 21, 2021 - Bourne Partners
Ashfield Engage, part of UDG Healthcare plc., announces the closure of the acquisition of Nuvera LLC, a US-based healthcare consulting firm specializing in patient support programs.
Welcome to Bourne, let's talk.

Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.